VRC-4219

Chemical Name: 2-[2-[3(S),6-Diamino-5(R)-fluorohexanoyl]-1-methylhydrazino]acetic acid; 3(S),6-Diamino-5(R)-fluorohexanoic acid 2-(carboxymethyl)-2-methylhydrazide
项目整合开发状态: Preclinical
项目研究机构: Vicuron Pharmaceuticals (Originator)
合成路线:The activation of N-Boc-L-aspartic acid 4-O-tert-butyl ester (I) with isopropyl chloroformate (II) in THF gives the mixed anhydride (III),which is reduced with NaBH4 to yield the hydroxyester (IV).The Swern oxidation of (IV) affords the aldehyde (V),which is condensed with the phosphonate (VI) by means of BuLi to provide the hexenedioic diester (VII).The stepwise reduction of (VII) first by means of H2 over Pd/C and then with NaBH4 gives rise to the omega-hydroxy hexanoate (VIII).This is treated first with MsCl and TEA and then with NaN3 to yield a diastereomeric mixture of azido hexanoates (IX) and (X).After separation,the desired isomer (X) is hydrolyzed with LiOH to afford the corresponding carboxylic acid (XI),which is condensed with 2-(1-methylhydrazino)acetic acid tert-butyl ester (XII) by means of HATU and DIEA to provide the corresponding hydrazide (XIII).The reduction of the azido group of (XIII) by means of H2 over Pd/C or with PPh3 in THF/water provides the corresponding amino derivative (XIV),which is finally hydrolyzed and N-deprotected by means of 4M HCl in dioxane to furnish the target fluorinated deoxynegamycin.